Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accumulated Expenses (2021 - 2026)

bioAffinity Technologies has reported Accumulated Expenses over the past 6 years, most recently at $2.0 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 118.18% to $2.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Mar 2026, up 118.18% year-over-year, with the annual reading at $1.7 million for FY2025, 59.1% up from the prior year.
  • Accumulated Expenses was $2.0 million for Q1 2026 at bioAffinity Technologies, up from $1.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $2.0 million in Q1 2026 and troughed at $281085.0 in Q1 2023.
  • The 5-year median for Accumulated Expenses is $969093.0 (2024), against an average of $1.0 million.
  • Year-over-year, Accumulated Expenses tumbled 59.76% in 2023 and then soared 214.25% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $541894.0 in 2022, then surged by 112.18% to $1.1 million in 2023, then dropped by 6.09% to $1.1 million in 2024, then soared by 59.1% to $1.7 million in 2025, then increased by 18.39% to $2.0 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Accumulated Expenses are $2.0 million (Q1 2026), $1.7 million (Q4 2025), and $984547.0 (Q3 2025).